Wall Street analysts expect Oncomed Pharmaceuticals Inc (NASDAQ:OMED) to announce sales of $5.10 million for the current quarter, according to Zacks. Three analysts have made estimates for Oncomed Pharmaceuticals’ earnings. The highest sales estimate is $5.11 million and the lowest is $5.10 million. Oncomed Pharmaceuticals reported sales of $6.22 million in the same quarter last year, which would suggest a negative year-over-year growth rate of 18%. The business is expected to announce its next quarterly earnings report on Wednesday, March 14th.
On average, analysts expect that Oncomed Pharmaceuticals will report full-year sales of $5.10 million for the current fiscal year, with estimates ranging from $22.50 million to $24.00 million. For the next fiscal year, analysts forecast that the company will report sales of $22.29 million per share, with estimates ranging from $20.00 million to $25.00 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side analysts that that provide coverage for Oncomed Pharmaceuticals.
OMED has been the subject of a number of analyst reports. Zacks Investment Research lowered Oncomed Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, January 6th. Cantor Fitzgerald set a $6.00 price target on Oncomed Pharmaceuticals and gave the company a “hold” rating in a research report on Thursday, January 4th. One analyst has rated the stock with a sell rating, seven have given a hold rating and two have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $5.81.
Oncomed Pharmaceuticals (NASDAQ:OMED) opened at $2.06 on Wednesday. Oncomed Pharmaceuticals has a twelve month low of $1.74 and a twelve month high of $10.89. The stock has a market capitalization of $77.98, a price-to-earnings ratio of -1.08 and a beta of 2.23.
About Oncomed Pharmaceuticals
OncoMed Pharmaceuticals, Inc (OncoMed) is a clinical-stage biopharmaceutical company. The Company focuses on discovering and developing therapeutics that address the fundamental biology driving cancer’s growth, resistance, recurrence and metastasis. The Company’s therapeutic candidates and preclinical programs include Demcizumab (Anti-DLL4, OMP-21M18), Tarextumab (Anti-Notch2/3, OMP-59R5), Vantictumab (anti-Fzd7, OMP-18R5), Ipafricept (Fzd8-Fc, OMP-54F28), Brontictuzumab (Anti-Notch1, OMP-52M51), Navicixizumab (Anti-DLL4/VEGF Bispecific, OMP-305B83), Anti-RSPO3 (OMP-131R10), Anti-TIGIT (OMP-313M32) and GITRL-Fc trimer (OMP-336B11).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Oncomed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncomed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.